MET ex14跳跃突变的检测应作为肺癌精准治疗的重要组成部分,NCCN指南,ESMO指南,CSCO指南均推荐广泛的分子图谱检测来识别肺癌驱动突变,包括EGFR, ALK, BRAF, MET ex14等。 针对MET ex14跳跃突变的靶向药物发展迅速,如卡马替尼、特泊替尼、赛沃替尼等均已在国外或国内获批相关适应症,其中卡马替尼作为国际创新药物目前...
9. Ella A Eklund, Clotilde Wiel, Henrik Fagman, et al. KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer.[J] .Cancers (Basel), 2022, 14: 0. 10. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2024版. 11. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidel...
基于GEOMETRY Mono-1优异的阳性结果,NCCN指南将卡马替尼作为MET ex14突变晚期NSCLC患者的一线优先推荐[7]。RECAP分析也进一步在真实世界中验证了卡马替尼的有效性和安全性。目前卡马替尼已在全球多个国家和地区获批,随着卡马替尼在海南博鳌和粤港澳...
9. Ella A Eklund, Clotilde Wiel, Henrik Fagman, et al. KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer.[J] .Cancers (Basel), 2022, 14: 0. 10. 中国临床肿瘤学会(CSCO)非小细胞...
Mutations in KRAS exon 2, BRAF and PIK3CA are commonly present in colorectal cancer (CRC) worldwide, but few data about RAS mutations outside KRAS exon 2 are available for Chinese CRCs. We, therefore, determined the mutation frequencies and prognostic va
In addition, the "09years of NCCN non-small cell lung cancer clinical practice guidelines"clearly pointed out: when the K-ras gene mutations if, it is not recommended inpatients with Tarceva (erlotinib Tarceva/ /Erlotinib) for molecular targeted therapy. ...
29. TheKRASG12Dmutation has an intrinsic wildtype and SOS1 guanine exchange activities while theKRASQ61mutation has deficiencies in GTP hydrolysis27,30. TheKRASG12Rmutation, which accounts for approximately 15% of theKRASmutations in pancreatic cancer but less than 1% of theKRASmutations in lung...
2. Role of KRAS in normal cell homeostasis and disease 3. Epidemiology of KRAS-activating mutations: incidence and biology in advanced NSCLC 4. Advances in the treatment of KRAS-mutant NSCLC 5. Overlap between tumor mutational burden, PD-L1 expression, co-mutations, and KRAS G12C-mutant NSCLC...
人类K-ras 基因突变检测试剂盒( PCR- 熔解曲线法)说明书 【产品名称】 通用名:人类 K-ras 基因突变检测试剂盒( PCR- 熔解曲线法) (PCR-Melting Curve Analysis) 英文名: Diagnostic kit for Mutations of Human K-ras Gene 【包装规格】 20 测试 / 盒 【预期用途】 K-ras 基因位于 12号染...
NCCN非小细胞肺癌诊疗指南早期将KRAS作为预测和预后生物标志物,优化后续诊疗策略,KRAS阳性突变患者仍采用无驱动基因治疗。现如今,KRAS检测在NSCLC诊疗中变得愈发重要。《NCCN非小细胞肺癌临床实践指南(2023年v3版)》一级推荐所有晚期或转移性疾病的NSCLC患者在治疗前均需进行KRAS基因检测⁸,用以指导KRAS G12C小分子...